The impact of plasma protein binding on toxic plasma drug concentration Online publication date: Wed, 02-Nov-2016
by Andreas Svennebring
International Journal of Computational Biology and Drug Design (IJCBDD), Vol. 9, No. 4, 2016
Abstract: Drugs with high plasma protein binding are relatively protected from first-pass hepatic metabolism. However, there are concerns about potential problems caused by high plasma protein binding, one of which is toxicity. Statistical analyses of plasma concentration thresholds for toxic and comatose-lethal effects of drugs by multiple linear regression (MLR) models indicate that high plasma protein binding is slightly associated with toxicity of drugs in general, but not in the high (≥90%) plasma protein binding range. Lipophilicity as determined by the octanol/water partition coefficient (Log P) is a major driver of acute toxicity, which can largely and perhaps entirely explain the higher acute toxicity of drugs with high plasma protein binding. Neither plasma protein binding nor lipophilicity have any relation to the therapeutic window of drugs.
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Computational Biology and Drug Design (IJCBDD):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email subs@inderscience.com